Visudyne

This page contains recent news articles, when available, and an overview of Visudyne but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

BC to approve two new drugs to treat disease that could cause ...  -  ‎Apr 8, 2009‎
BC currently funds only one drug - Visudyne - but it hasn't proven effective for many seniors who've had to spend over $1600 per treatment every six weeks The Canadian Press

Research and Markets: Analysis of AERS Data on AMD Therapeutics  -  ‎Mar 31, 2009‎
This report provides a detailed analysis on the adverse events reported against the prescribed AMD drugs namely Lucentis, Macugen and Visudyne for the Business Wire (press release)

QLT Inc.(NASDAQ:QLTI) - Eligard sales to support top-line growth ...  -  ‎Apr 8, 2009‎
However, Visudyne continued to demonstrate weak performance during the quarter. We believe Visudyne sales will continue to be negatively impacted, Research Oracle

Acucela Hires Head of Clinical Development and Regulatory Affairs  -  ‎Mar 30, 2009‎
During the past 19 years, Dr. Boman has played a key role in successfully submitting 15 drug applications for approval, including Visudyne while at QLT. Business Wire (press release)

黄斑部病�?�能�?�治好?  -  ‎Apr 10, 2009‎
...这�?光动力学治疗将一�?特殊的光�?剂Visudyne注入血管，当其在眼内积累到一定�?时，用一�?特定的激光将光�?剂激活，激活的光�?剂释放大�?的自由基和�?��?氧，破�??细胞医盟网健康资讯

Research, is needed now more than ever  -  18 Mar 2009
...the creation of drug-eluting stents, the design of Visudyne for preventing blindness in seniors) and makes our lives easier (the Internet tools WebCT, The Gazette (Montreal)

QLT denied rehearing in MEEI claim  -  ‎Feb 24, 2009‎
QLT estimated that the amount of damages and interest that QLT is required to pay MEEI could be about $113.2 million, based on net sales of Visudyne of Reuters

QLT records profit; still 'challenges to overcome'  -  ‎Feb 20, 2009‎
Still, with sales of the company's Visudyne antiblindness eye treatment on the wane and with its inability to find a buyer for its Eligard business, Globe and Mail

Economic and Clinical Value: Key Drivers for New Product ...  -  ‎Mar 2, 2009‎
As a result, the Visudyne product team made assumptions that were not in the end supported by economic and clinical data. Visudyne received approval from Medical Device Link (press release)

Business Briefs  -  ‎Feb 20, 2009‎
Visudyne revenue fell 12.7 per cent to $11.9 million, while product and royalty revenue related to Eligard rose 41.4 per cent to $24 million. London Free Press

QLT announces completion of Phase Ia safety trial of its synthetic ...  -  ‎Mar 12, 2009‎
QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of PR Newswire (press release)

QLT rises to profit on Eligard sales  -  ‎Feb 19, 2009‎
Quarterly revenue for Visudyne, which the company shares with global marketing partner Novartis, fell 32.7 percent to $30.6 million, while revenue from Alibaba News Channel

Research Oracle roundup for 20 February 2009  -  ‎Feb 20, 2009‎
...we remain concerned over QLT’s weak product pipeline, with no strong product expected over the next 2 years and weakening sales of Visudyne. Research Oracle

AMD najczęstszą przyczyną ślepoty osób starszych  -  ‎Mar 5, 2009‎
Obecnie odchodzi się od laseroterapii na rzecz terapii fotodynamicznej z werteporfiną (preparat Visudyne). Polega ona na wprowadzeniu do krwiobiegu barwnika Puls Medycyny

QLT says Q4 sales of Visudyne down 32.7 per cent compared with ...  -  Jan 12, 2009
VANCOUVER, BC - QLT Inc. (TSX:QLT) said Monday that global sales of Visudyne in the fourth quarter were down 32.7 per cent compared with a year ago. News1130,

QLT Announces Appeal Court Decision on Massachusetts Eye and Ear ...  -  Jan 12, 2009
Unless the decision is altered on further review, based on net sales of Visudyne(R) through December 31, 2008 of approximately $2.6 billion, QLT estimates FOXBusiness

Drug maker QLT Inc. values share buyback at $50 million  -  Jan 27, 2009
Based on net sales of Visudyne through Dec. 31 of approximately $2.6 billion, QLT estimates it will be required to pay about US$113.2 million. The Canadian Press,

QLT announces preliminary results of tender offer  -  Jan 27, 2009
QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of PR Newswire (press release),

QLT tenders for $50 million  -  Feb 1, 2009
The company, which pioneered the once hugely anticipated blindness cure Visudyne, has been fighting increased competition and heavy losses for years. The Province,

Vancouver biotech closes US$50 million buyback in bid to raise ...  -  Jan 28, 2009
QLT recently reported a 34% annual decline in global sales of its signature Visudyne macular degeneration drug to US$141.9 million for the year ending Business in Vancouver,

BRIEF-QLT Q4 Visudyne sales down 32.7 pct  -  Jan 12, 2009
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior Forbes,

US appeal court backs unfair trading decision  -  Jan 14, 2009
Based on net sales of Visudyne through Dec. 31 of approximately $2.6 billion, QLT estimates it will be required to pay the Massachusetts Eye and Ear Toronto Star,

NovaGold reassures investors over review  -  Jan 22, 2009
In the original 2007 judgment, QLT was ordered to pay MEEI damages equal to 3.01 percent on past, present and future worldwide net sales of Visudyne plus Business Edge,

Other News To Note  -  Jan 13, 2009
5798349 and certain of MEEI's research results related to QLT's Visudyne. The Court of Appeals upheld the liability and damages aspects of the 2007 judgment TMCnet

BRIEF-QLT Q4 Visudyne sales down 32.7 pct  -  Jan 12, 2009
Interactive Investor Trading Limited, trading as "Interactive Investor", is authorised and regulated by the Financial Services Authority. Interactive Investor,

QLT announces new expiration date of tender offer  -  Jan 15, 2009
...photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. FOXBusiness

Ranibizumab Helps Patients with Wet Macular Degeneration Function ...  -  Jan 16, 2009
16 -- For patients with neovascular age-related macular degeneration, ranibizumab (Lucentis) outperformed photodynamic therapy with verteporfin (Visudyne) MedPage Today,

Business News  -  Jan 13, 2009
3.01 per cent of past, present and future worldwide sales of Visudyne - a treatment for macular degeneration - plus interest and certain legal fees. AOL Canada,

Business News  -  Jan 12, 2009
VANCOUVER, BC - QLT Inc. (TSX:QLT) said Monday that global sales of Visudyne in the fourth quarter were down 32.7 per cent compared with a year ago. AOL Canada,

QLT announces interim results of radical study evaluating Visudyne ...  -  Dec 16, 2008
...(CA:QLT: news, chart, profile) today announced six-month results from an interim analysis for the Phase II RADICAL study (Reduced Fluence Visudyne MarketWatch

QLT shares buck falling market on buyback  -  Dec 1, 2008
QLT has been selling off assets since January, when it announced a plan to focus on its macular degeneration treatment Visudyne. CNNMoney.com

QLT announces commencement of tender offer  -  Dec 5, 2008
QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of MarketWatch

QLT to repurchase up to US$ 50 million of common shares - Modified ...  -  Dec 1, 2008
QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of SYS-CON Media,

Cerimon Pharmaceuticals Appoints James S. Shannon, MD, to Board of ...  -  Dec 2, 2008
...including Diovan(R), Tekturna(R), Gleevec(R), Femara(R), Zometa(R), Reclast(R), Lucentis(R) (ex-US), Starlix(R), Visudyne(R) and Xolair(R). SYS-CON Brasil,

QLT eyes share buyback as divestitures provide cash  -  Oct 28, 2008
Third-quarter revenue fell 25.6 percent to $10.9 million as a drop in sales of Visudyne, aimed at fighting macular degeneration, was only partly offset by Forbes,

QLT announces third quarter results for 2008  -  Oct 28, 2008
Also, our royalty revenue from Visudyne(R) and Eligard(R) continue to be significant to the Company and provide additional funding for our internal SYS-CON Brasil,

QLT Inc - Premium Company Profile - New Research Report on ...  -  Nov 14, 2008
QLT has two marketed products: Visudyne for the treatment of wet age-related macular degeneration (AMD), pathologic myopia and presumed ocular Live-PR.com (Pressemitteilung),

TOP MARKET NEWS  -  Oct 28, 2008
...(RTTNews) - Global Visudyne sales declined 30.1% during the quarter, while worldwide sales of Eligard increased 18.3% over the third quarter of 2007. RTT News,

QLT announces encouraging Phase II data from core study of Punctal ...  -  Oct 28, 2008
QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of SYS-CON Media,

QLT Inc. (NASDAQ:QLTI) - Operating performance exceeded our ...  -  Oct 29, 2008
...we remain concerned for QLT’s weak product pipeline, with no strong product expected over the next 2 years and weakening sales of Visudyne. Research Oracle,

TSX may rise on oil, banks may offset  -  Oct 28, 2008
It also said it expected sales of Visudyne, aimed at fighting macular degeneration, for the year will be at the low end of its forecast range. Calgary Herald,

Technical Trade Alert on Market Movers: INCY, QLTI, LINTA, PDGI ...  -  Nov 10, 2008
QLT is a global biopharmaceutical company with two commercial products, Visudyne and Eligard, which were derived from its two technology platforms, Baystreet.ca,

Research Oracle roundup for 29 October 2008  -  Oct 29, 2008
...we remain concerned for QLT’s weak product pipeline, with no strong product expected over the next 2 years and weakening sales of Visudyne. Research Oracle,

QLT Inc reports third quarter 2008 sales of Visudyne  -  21 Oct 2008
The company reported global sales of USD34.1m for the third quarter 2008 for Visudyne, reflecting a decline of 30.1% over global sales reported in the third Trading Markets (press release),

UPDATE 1-QLT's Visudyne sales drop 30 percent  -  Oct 20, 2008
Vancouver, British Columbia-based QLT said the drop in Visudyne sales was primarily due to the approval in Europe of alternative therapeutics for Reuters

QLT announces third quarter 2008 Visudyne(R) sales  -  Oct 20, 2008
The drop in Visudyne sales was primarily due to the approval and reimbursement in Europe of alternative therapeutics for age-related macular degeneration. SYS-CON Brasil (Assinatura),

QLT q3 Visudyne global sales down 30.1% - quick facts  -  Oct 20, 2008
TO: News ) said that that Novartis AG (NVS: News ) announced global sales of QLT's Visudyne product of US$34.1 million for the third quarter, a decrease of RTT News,

Bay Street Stocks Remain Higher - Canadian Commentary  -  Oct 20, 2008
TO) was flat after it was announced that global sales of its Visudyne product came in at US$34.1 million for the third quarter, a decrease of 30.1% from RTT News,

Market Report -- In Play (QLTI)  -  Oct 20, 2008
QLT Inc says sales its Visudyne product were $34.1 mln for Q3 ended September 30, 2008. Co announces that Novartis AG announced global sales of its Visudyne MSN Money

QLT announces the initiation of a Phase I trial of its synthetic ...  -  Oct 9, 2008
...<< QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of Canada NewsWire (press release),

Just don't call it pot  -  Oct 7, 2008
Levy joined the board, bringing her track record as the founder of Vancouver-based biotech QLT Inc., maker of the hit anti-blindness drug, Visudyne. Financial Post,

Photodynamic therapy appears less effective in patients taking aspirin  -  Oct 9, 2008
Dr. Stoltz and colleagues conducted a retrospective chart review on 244 eyes of 222 patients who underwent PDT with Visudyne (verteporfin, Novartis/QLT) OSN SuperSite (subscription),

Tekmira Pharmaceuticals Expands Executive Management Team  -  Sep 29, 2008
During his tenure at QLT, Dr. Lutwyche contributed to the development and commercialization of Visudyne as well as leading manufacturing and chemistry Market Wire (press release)

Η ηλικιακή εκφ�?λιση ωχ�?άς κηλίδας κ�?�?ια αιτία σοβα�?ής απώλειας ...  -  Sep 25, 2008
δ�?ουν απ'Α ευθείας, δεν έχουν συστηματικές ανεπιθ�?μητες ενέ�?γειες και ουσιαστικά αντικατέστησαν τα laser και τη φωτοδυναμική θε�?απεία με visudyne. Εξπ�?ές,

QLT Announces Completion of the Redemption of 3% Convertible ...  -  16 Sep 2008
QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of PharmaLive.com (press release),

QLT to licence its Atrigel technology  -  Aug 26, 2008
It's the latest divestiture this summer for Vancouver-based QLT, maker of the Visudyne treatment for an age-related form of blindness, and brings the total Toronto Star,

QLT Inc. (NASDAQ:QLTI) - Visudyne sales prospects remain cautious ...  -  Aug 21, 2008
In 2Q 08, QLT Inc. (QLT) reported decline in revenues from its flagship product, Visudyne, resulting in weak performance of the company during the quarter. Research Oracle,

QLT Inc. Q2 2008 Earnings Call Transcript  -  Aug 20, 2008
Now, I want to turn to product sales for Visudyne and Eligard. Global Visudyne sales in the second quarter were $40.7 million which is a Seeking Alpha,

QLT completes Cdn$65.5 million real estate transaction  -  Sep 3, 2008
...<< QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of CNW Telbec (Communiqués de presse),

Research Oracle roundup for 21 August 2008  -  Aug 21, 2008
In 2Q 08, QLT Inc. (NASDAQ:QLTI) reported decline in revenues from its flagship product, Visudyne, resulting in weak performance of the company during the Research Oracle,

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.